SG11201808777UA - Improvements in cancer treatment - Google Patents

Improvements in cancer treatment

Info

Publication number
SG11201808777UA
SG11201808777UA SG11201808777UA SG11201808777UA SG11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA
Authority
SG
Singapore
Prior art keywords
international
pct
turramurra
unless
box
Prior art date
Application number
SG11201808777UA
Inventor
Graham Kelly
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of SG11201808777UA publication Critical patent/SG11201808777UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110101111111110111011111111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number ..... .....1 (43) International Publication Date WO 2017/173474 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 31/352 (2006.01) A61K 47/46 (2006.01) A61K 31/382 (2006.01) A61K 9/02 (2006.01) A61K 31/473 (2006.01) A61P 35/00 (2006.01) A61K 47/44 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (21) International Application Number: PCT/AU2016/050674 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 28 July 2016 (28.07.2016) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: 62/318,946 6 April 2016 (06.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: NOXOPHARM LIMITED [AU/AU]; PO Box 824, Turramurra, New South Wales 2074 (AU). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: KELLY, Graham; PO Box 824, Turramurra, Declarations under Rule 4.17: New South Wales 2074 (AU). — of inventorship (Rule 4.17(iv)) (74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level 46, 101 Collins Street, Melbourne, Victoria 3000 (AU). Published: Designated States (unless otherwise indicated, for every (81) — with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, Il 7r IN 7r M IN 11 IN 11 © \" (54) Title: IMPROVEMENTS IN CANCER TREATMENT (:) .,.. (57) : The invention relates to cancer therapy, especially to cytotoxic agents and chemo-sensitizing and radio-sensitising agents, particularly isoflavonoids, and to improving the bioavailability of same.
SG11201808777UA 2016-04-06 2016-07-28 Improvements in cancer treatment SG11201808777UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment

Publications (1)

Publication Number Publication Date
SG11201808777UA true SG11201808777UA (en) 2018-11-29

Family

ID=60000141

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808777UA SG11201808777UA (en) 2016-04-06 2016-07-28 Improvements in cancer treatment

Country Status (11)

Country Link
US (2) US20190160004A1 (en)
EP (2) EP3939583A1 (en)
JP (1) JP2019510830A (en)
KR (1) KR20190016017A (en)
CN (1) CN109475522A (en)
AU (2) AU2016401508B2 (en)
CA (1) CA3058479A1 (en)
IL (1) IL262143A (en)
RU (1) RU2018137897A (en)
SG (1) SG11201808777UA (en)
WO (1) WO2017173474A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173496A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2022204757A1 (en) * 2021-03-30 2022-10-06 Noxopharm Limited Improved isoflavone formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US9173866B2 (en) * 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
EP1686981A4 (en) 2003-11-19 2011-02-23 Novogen Res Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
DE102005009515A1 (en) * 2005-02-25 2006-09-07 Exner, Heinrich, Dr. A process for preparing a preparation of a DMSO-containing solid silicone oil emulsion for binding reactive oxygen compounds in the body of humans and animals
WO2007035515A2 (en) * 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
CA2691201A1 (en) * 2007-06-29 2009-01-08 Novogen Research Pty Ltd 2-substituted isoflavonoid compounds, medicaments and uses
CN102215841A (en) * 2008-08-29 2011-10-12 诺沃根研究控股有限公司 Immunomodulating activities
KR20110004525A (en) * 2009-07-08 2011-01-14 동의대학교 산학협력단 Composition for treatment of liver cancer comprising genistein and trail

Also Published As

Publication number Publication date
RU2018137897A3 (en) 2020-05-13
CN109475522A (en) 2019-03-15
AU2016401508A1 (en) 2018-11-01
RU2018137897A (en) 2020-05-13
AU2016401508B2 (en) 2020-03-26
CA3058479A1 (en) 2017-10-12
IL262143A (en) 2018-11-29
US20190160004A1 (en) 2019-05-30
US20210338576A1 (en) 2021-11-04
JP2019510830A (en) 2019-04-18
EP3439651A1 (en) 2019-02-13
EP3939583A1 (en) 2022-01-19
WO2017173474A1 (en) 2017-10-12
KR20190016017A (en) 2019-02-15
AU2020204172A1 (en) 2020-07-09
EP3439651A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
SG11201804934PA (en) Novel Compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805835WA (en) Modified oncolytic virus
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201803906PA (en) Control of cellular redox levels
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407200TA (en) Liquid formulation
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909837YA (en) Methods for treating lung disorders
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201805755SA (en) Methods of administering hepcidin
SG11201809882XA (en) Pharmaceutical combinations for treating cancer